SEC-sourced researchBeta
TGTX
TG THERAPEUTICS, INC.
Company comparison ↗
Data passport
- CIK
- 0001001316
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Sep 14, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 233,662,000.0000 | Feb 27, 2026 |
| December 2024 | 329,004,000.0000 | Feb 27, 2026 |
| December 2025 | 616,287,000.0000 | Feb 27, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 616,287,000.0000 | 447,179,000.0000 | -24,772,000.0000 | 1,063,253,000.0000 | 415,233,000.0000 | Feb 27, 2026 |
| December 2024 | 329,004,000.0000 | 23,383,000.0000 | -40,517,000.0000 | 577,690,000.0000 | 355,326,000.0000 | Feb 27, 2026 |
| December 2023 | 233,662,000.0000 | 12,672,000.0000 | -31,413,000.0000 | — | — | Feb 27, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $616.29M | December 2025 | Feb 27, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $329M | December 2024 | Feb 27, 2026 | 10-K |
| Net incomeNetIncomeLoss | $447.18M | December 2025 | Feb 27, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$24.77M | December 2025 | Feb 27, 2026 | 10-K |
| Total assetsAssets | $1.06B | December 2025 | Feb 27, 2026 | 10-K |
| Total liabilitiesLiabilities | $415.23M | December 2025 | Feb 27, 2026 | 10-K |